Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN)

Piper Sandler analyst David Amsellem reiterated an Overweight rating and $41.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).

The analyst commented, "Supernus presented interim data from its open-label Phase IIa study evaluating SPN-817 (oral synthetic form of acetylcholinesterase inhibitor huperzine A) in focal onset seizures. SPN-817's seizure frequency reduction profile in our view looks competitive with that of other widely used anti-seizure medications (ASM) (the caveat of course is that there was no placebo control). Frequent adverse events (AE) are a consideration, though we did not see anything that rose to "red flag" levels. We believe that at current levels (EV/2025E EBITDA of ~7x), there is little value being ascribed to SPN-817 and other pipeline assets (e.g., SPN-820 in treatment-resistant depression), in the context of strong visibility into considerable longer-term EBITDA growth from the base business (i.e., namely Qelbree and Gocovri) off of the 2024 trough year (owing to the loss of exclusivity of Trokendi XR and Oxtellar XR). "

For an analyst ratings summary and ratings history on Supernus Pharmaceuticals click here. For more ratings news on Supernus Pharmaceuticals click here.

Shares of Supernus Pharmaceuticals closed at $27.77 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'
• Abivax (ABVX) PT Lowered to $136 at Wolfe Research